Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line

Katsuyuki Takahashi, Masako Tanaka, Azusa Inagaki, Hideki Wanibuchi, Yasukatsu Izumi, Katsuyuki Miura, Katsuya Nagayama, Masayuki Shiota, Hiroshi Iwao

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Triple-negative breast cancers (TNBCs) are defined as tumors that lack expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Clinically, TNBC patients are treated with cytotoxic drugs including 5-fluorouracil (5-FU). However, TNBCs develop resistance to such drugs after a series of treatments. To elucidate the mechanisms of drug resistance, establishment of drug-resistant cancer cell lines should be one of the most useful model systems. However, 5-FU-resistant TNBC cell lines have not been previously reported. In this study, we established a 5-FU-resistant cell line, MDA-MB-231/5-FU, from the human TNBC cell line MDA-MB-231, by repeated exposure to stepwise increases in the concentration of 5-FU. The IC50 value of 5-FU for MDA-MB-231/5-FU was 5.5-fold that for the parental cells. The MDA-MB-231/5-FU cell line acquired resistance to not only 5-FU, but also vinorelbine, paclitaxel and gemcitabine. Additionally, we performed iTRAQ-based quantitative proteomics in MDA-MB-231/5-FU cells and the parental cells in order to characterize MDA-MB-231/5-FU. The proteins upregulated in the newly established cells were mainly classified into the categories of 'DNA recombination', 'cell cycle', 'complex assembly', 'cytoskeleton organization', 'transport' and 'negative regulation of cell death'. These proteins may be related to mechanisms of drug resistance in TNBCs. Our established MDA-MB-231/5-FU cell line should be a useful tool for identifying new mechanisms of drug resistance and new drug targets in TNBCs.

Original languageEnglish
Pages (from-to)1985-1991
Number of pages7
JournalInternational Journal of Oncology
Volume43
Issue number6
DOIs
Publication statusPublished - 2013 Dec
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Fluorouracil
Cell Line
Drug Resistance
gemcitabine
Pharmaceutical Preparations
Progesterone Receptors
Paclitaxel
Cytoskeleton
Estrogen Receptors
Proteomics
Genetic Recombination
Inhibitory Concentration 50
MB 5

Keywords

  • 5-fluorouracil
  • Drug-resistant cell
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. / Takahashi, Katsuyuki; Tanaka, Masako; Inagaki, Azusa; Wanibuchi, Hideki; Izumi, Yasukatsu; Miura, Katsuyuki; Nagayama, Katsuya; Shiota, Masayuki; Iwao, Hiroshi.

In: International Journal of Oncology, Vol. 43, No. 6, 12.2013, p. 1985-1991.

Research output: Contribution to journalArticle

Takahashi, K, Tanaka, M, Inagaki, A, Wanibuchi, H, Izumi, Y, Miura, K, Nagayama, K, Shiota, M & Iwao, H 2013, 'Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line', International Journal of Oncology, vol. 43, no. 6, pp. 1985-1991. https://doi.org/10.3892/ijo.2013.2135
Takahashi, Katsuyuki ; Tanaka, Masako ; Inagaki, Azusa ; Wanibuchi, Hideki ; Izumi, Yasukatsu ; Miura, Katsuyuki ; Nagayama, Katsuya ; Shiota, Masayuki ; Iwao, Hiroshi. / Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. In: International Journal of Oncology. 2013 ; Vol. 43, No. 6. pp. 1985-1991.
@article{bb1024d23d814b50bccef52776b46a40,
title = "Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line",
abstract = "Triple-negative breast cancers (TNBCs) are defined as tumors that lack expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Clinically, TNBC patients are treated with cytotoxic drugs including 5-fluorouracil (5-FU). However, TNBCs develop resistance to such drugs after a series of treatments. To elucidate the mechanisms of drug resistance, establishment of drug-resistant cancer cell lines should be one of the most useful model systems. However, 5-FU-resistant TNBC cell lines have not been previously reported. In this study, we established a 5-FU-resistant cell line, MDA-MB-231/5-FU, from the human TNBC cell line MDA-MB-231, by repeated exposure to stepwise increases in the concentration of 5-FU. The IC50 value of 5-FU for MDA-MB-231/5-FU was 5.5-fold that for the parental cells. The MDA-MB-231/5-FU cell line acquired resistance to not only 5-FU, but also vinorelbine, paclitaxel and gemcitabine. Additionally, we performed iTRAQ-based quantitative proteomics in MDA-MB-231/5-FU cells and the parental cells in order to characterize MDA-MB-231/5-FU. The proteins upregulated in the newly established cells were mainly classified into the categories of 'DNA recombination', 'cell cycle', 'complex assembly', 'cytoskeleton organization', 'transport' and 'negative regulation of cell death'. These proteins may be related to mechanisms of drug resistance in TNBCs. Our established MDA-MB-231/5-FU cell line should be a useful tool for identifying new mechanisms of drug resistance and new drug targets in TNBCs.",
keywords = "5-fluorouracil, Drug-resistant cell, Triple-negative breast cancer",
author = "Katsuyuki Takahashi and Masako Tanaka and Azusa Inagaki and Hideki Wanibuchi and Yasukatsu Izumi and Katsuyuki Miura and Katsuya Nagayama and Masayuki Shiota and Hiroshi Iwao",
year = "2013",
month = "12",
doi = "10.3892/ijo.2013.2135",
language = "English",
volume = "43",
pages = "1985--1991",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line

AU - Takahashi, Katsuyuki

AU - Tanaka, Masako

AU - Inagaki, Azusa

AU - Wanibuchi, Hideki

AU - Izumi, Yasukatsu

AU - Miura, Katsuyuki

AU - Nagayama, Katsuya

AU - Shiota, Masayuki

AU - Iwao, Hiroshi

PY - 2013/12

Y1 - 2013/12

N2 - Triple-negative breast cancers (TNBCs) are defined as tumors that lack expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Clinically, TNBC patients are treated with cytotoxic drugs including 5-fluorouracil (5-FU). However, TNBCs develop resistance to such drugs after a series of treatments. To elucidate the mechanisms of drug resistance, establishment of drug-resistant cancer cell lines should be one of the most useful model systems. However, 5-FU-resistant TNBC cell lines have not been previously reported. In this study, we established a 5-FU-resistant cell line, MDA-MB-231/5-FU, from the human TNBC cell line MDA-MB-231, by repeated exposure to stepwise increases in the concentration of 5-FU. The IC50 value of 5-FU for MDA-MB-231/5-FU was 5.5-fold that for the parental cells. The MDA-MB-231/5-FU cell line acquired resistance to not only 5-FU, but also vinorelbine, paclitaxel and gemcitabine. Additionally, we performed iTRAQ-based quantitative proteomics in MDA-MB-231/5-FU cells and the parental cells in order to characterize MDA-MB-231/5-FU. The proteins upregulated in the newly established cells were mainly classified into the categories of 'DNA recombination', 'cell cycle', 'complex assembly', 'cytoskeleton organization', 'transport' and 'negative regulation of cell death'. These proteins may be related to mechanisms of drug resistance in TNBCs. Our established MDA-MB-231/5-FU cell line should be a useful tool for identifying new mechanisms of drug resistance and new drug targets in TNBCs.

AB - Triple-negative breast cancers (TNBCs) are defined as tumors that lack expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Clinically, TNBC patients are treated with cytotoxic drugs including 5-fluorouracil (5-FU). However, TNBCs develop resistance to such drugs after a series of treatments. To elucidate the mechanisms of drug resistance, establishment of drug-resistant cancer cell lines should be one of the most useful model systems. However, 5-FU-resistant TNBC cell lines have not been previously reported. In this study, we established a 5-FU-resistant cell line, MDA-MB-231/5-FU, from the human TNBC cell line MDA-MB-231, by repeated exposure to stepwise increases in the concentration of 5-FU. The IC50 value of 5-FU for MDA-MB-231/5-FU was 5.5-fold that for the parental cells. The MDA-MB-231/5-FU cell line acquired resistance to not only 5-FU, but also vinorelbine, paclitaxel and gemcitabine. Additionally, we performed iTRAQ-based quantitative proteomics in MDA-MB-231/5-FU cells and the parental cells in order to characterize MDA-MB-231/5-FU. The proteins upregulated in the newly established cells were mainly classified into the categories of 'DNA recombination', 'cell cycle', 'complex assembly', 'cytoskeleton organization', 'transport' and 'negative regulation of cell death'. These proteins may be related to mechanisms of drug resistance in TNBCs. Our established MDA-MB-231/5-FU cell line should be a useful tool for identifying new mechanisms of drug resistance and new drug targets in TNBCs.

KW - 5-fluorouracil

KW - Drug-resistant cell

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84891938948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891938948&partnerID=8YFLogxK

U2 - 10.3892/ijo.2013.2135

DO - 10.3892/ijo.2013.2135

M3 - Article

VL - 43

SP - 1985

EP - 1991

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -